Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
Authors:
- on behalf of the FIELD study investigatorsOIon behalf of the FIELD study investigators
- M.-R. TaskinenMTM.-R. Taskinen
- J. D. BestJBJ. D. Best
Open Access
- 6 June 2010
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 53 (9) , 1846-1855
Abstract
The apolipoprotein B (ApoB):apolipoprotein A (ApoA)-I ratio may be a better indicator of cardiovascular disease (CVD) risk in people with type 2 diabetes than traditional lipid risk markers (LDL-cholesterol, HDL-cholesterol and triacylglycerol), but whether the ApoB:ApoA-I ratio should be used to indicate lipid-lowering therapy is still debated.Keywords
This publication has 50 references indexed in Scilit:
- Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best PracticesClinical Chemistry, 2009
- Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease RiskJACC, 2009
- The importance of non–HDL cholesterol reporting in lipid managementJournal of Clinical Lipidology, 2008
- Lipoprotein Management in Patients With Cardiometabolic RiskDiabetes Care, 2008
- LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL managementJournal of Clinical Lipidology, 2007
- Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to goCurrent Opinion in Endocrinology, Diabetes and Obesity, 2007
- Apolipoproteins as markers and managers of coronary riskQJM: An International Journal of Medicine, 2006
- Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panelJournal of Internal Medicine, 2006
- Non-HDL Cholesterol and Apolipoprotein B Predict Cardiovascular Disease Events Among Men With Type 2 DiabetesDiabetes Care, 2004
- High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective studyThe Lancet, 2001